A retrospective, single centre study identifying pseudoprogression from progression with DCE-MRI perfusion in metastatic melanoma treated with immunotherapy
Latest Information Update: 11 Nov 2020
At a glance
- Drugs Flanvotumab (Primary) ; Ipilimumab (Primary) ; Ipilimumab/nivolumab (Primary) ; Lirilumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary) ; Pidilizumab (Primary)
- Indications Brain metastases; Malignant melanoma
- Focus Therapeutic Use
- 11 Nov 2020 New trial record